IDL Diagnostics (IDLDX) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 2025 were KSEK 10,143, down from KSEK 15,273 in Q2 2024, with a similar trend for the first half of the year.

• Profit after financial items for Q2 2025 was KSEK -14,889, compared to KSEK -13,054 in Q2 2024.

• Cash and cash equivalents at the end of Q2 2025 stood at KSEK 44,265, down from KSEK 48,705 a year earlier.

• EBITDA for Q2 2025 was KSEK -4,757, compared to KSEK -1,943 in Q2 2024.

• The company changed its name from AroCell to IDL Diagnostics and expanded its partnership with Concile to boost international sales.

Financial highlights

• Net sales for Q2 2025: KSEK 10,143 (Q2 2024: KSEK 15,273); H1 2025: KSEK 25,451 (H1 2024: KSEK 28,076).

• Gross margin excluding goodwill amortization for Q2 2025: 47.1% (Q2 2024: 50.6%).

• Profit after financial items for Q2 2025: KSEK -14,889 (Q2 2024: KSEK -13,054); H1 2025: KSEK -27,217 (H1 2024: KSEK -23,594).

• Cash flow from operating activities for Q2 2025: KSEK -1,798 (Q2 2024: KSEK 2,767).

• Earnings per share for Q2 2025: SEK -0.06 (Q2 2024: SEK -0.06).

Outlook and guidance

• The company aims to maintain strong positions in established markets and expand into new ones, focusing on product development and competitiveness.

• The cancer diagnostics market is expected to grow significantly, with IDL Diagnostics positioned to benefit from increased demand for biomarkers and new technologies.